Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 170 participants.

Also called NCT06787430

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06787430
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06787430. Randomized; triple masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2026-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
Acronym
NORMAL
Condition
STEMI - ST-segment Elevation Myocardial Infarction
Intervention (Drug)
nicorandil
Intervention (Drug)
Saline (NaCl 0,9 %) (placebo)
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct06787430
Content hash
22d7cb66aa9c60b60e5f15797a6072dbe804255045bda6ebafe97e001af10edd